Saskia Pret 1/8/26 Saskia Pret 1/8/26 VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS Read More Saskia Pret 12/3/25 Saskia Pret 12/3/25 VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS Read More Saskia Pret 10/2/25 Saskia Pret 10/2/25 VectorY at ESGCT showcasing Innovation in Vectorized Antibody Therapies for CNS Disorders Read More Saskia Pret 9/18/25 Saskia Pret 9/18/25 VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid Read More Saskia Pret 5/27/25 Saskia Pret 5/27/25 VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer Read More Saskia Pret 5/7/25 Saskia Pret 5/7/25 VectorY Therapeutics to Present Preclinical Data on Novel ALS Therapeutic Strategy at Target ALS Conference in Boston Read More Saskia Pret 4/29/25 Saskia Pret 4/29/25 VectorY Therapeutics Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy Annual Meeting 2025 Read More Saskia Pret 4/1/25 Saskia Pret 4/1/25 VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer Read More Saskia Pret 12/16/24 Saskia Pret 12/16/24 VectorY Strengthens Leadership Team with appointment of Jim Scibetta as new CEO Read More Saskia Pret 7/9/24 Saskia Pret 7/9/24 VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board Read More Saskia Pret 6/17/24 Saskia Pret 6/17/24 UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study Read More Saskia Pret 6/14/24 Saskia Pret 6/14/24 VectorY to participate in key sector events in June 2024 Read More Saskia Pret 1/18/24 Saskia Pret 1/18/24 VectorY appoints Khurem Farooq to Board of Directors Read More Saskia Pret 11/13/23 Saskia Pret 11/13/23 VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative Diseases Read More Saskia Pret 5/1/23 Saskia Pret 5/1/23 VectorY to Present at the ASGCT Annual Meeting in May 2023 Read More Sariette Witte 4/14/23 Sariette Witte 4/14/23 VectorY to Present at the Bio€quity Europe Conference in May Read More Sariette Witte 4/5/23 Sariette Witte 4/5/23 VectorY to Participate in Key Sector Conferences in April 2023 Read More Sariette Witte 3/20/23 Sariette Witte 3/20/23 VectorY Appoints Michael Wyzga as CFO and adds Jean Franchi to its Board of Directors Read More Sariette Witte 1/19/23 Sariette Witte 1/19/23 VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters Read More Sariette Witte 1/10/23 Sariette Witte 1/10/23 Launching VectorY’s new corporate identity Read More Older Posts
Saskia Pret 1/8/26 Saskia Pret 1/8/26 VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS Read More
Saskia Pret 12/3/25 Saskia Pret 12/3/25 VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS Read More
Saskia Pret 10/2/25 Saskia Pret 10/2/25 VectorY at ESGCT showcasing Innovation in Vectorized Antibody Therapies for CNS Disorders Read More
Saskia Pret 9/18/25 Saskia Pret 9/18/25 VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid Read More
Saskia Pret 5/27/25 Saskia Pret 5/27/25 VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer Read More
Saskia Pret 5/7/25 Saskia Pret 5/7/25 VectorY Therapeutics to Present Preclinical Data on Novel ALS Therapeutic Strategy at Target ALS Conference in Boston Read More
Saskia Pret 4/29/25 Saskia Pret 4/29/25 VectorY Therapeutics Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy Annual Meeting 2025 Read More
Saskia Pret 4/1/25 Saskia Pret 4/1/25 VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer Read More
Saskia Pret 12/16/24 Saskia Pret 12/16/24 VectorY Strengthens Leadership Team with appointment of Jim Scibetta as new CEO Read More
Saskia Pret 7/9/24 Saskia Pret 7/9/24 VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board Read More
Saskia Pret 6/17/24 Saskia Pret 6/17/24 UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study Read More
Saskia Pret 6/14/24 Saskia Pret 6/14/24 VectorY to participate in key sector events in June 2024 Read More
Saskia Pret 1/18/24 Saskia Pret 1/18/24 VectorY appoints Khurem Farooq to Board of Directors Read More
Saskia Pret 11/13/23 Saskia Pret 11/13/23 VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative Diseases Read More
Saskia Pret 5/1/23 Saskia Pret 5/1/23 VectorY to Present at the ASGCT Annual Meeting in May 2023 Read More
Sariette Witte 4/14/23 Sariette Witte 4/14/23 VectorY to Present at the Bio€quity Europe Conference in May Read More
Sariette Witte 4/5/23 Sariette Witte 4/5/23 VectorY to Participate in Key Sector Conferences in April 2023 Read More
Sariette Witte 3/20/23 Sariette Witte 3/20/23 VectorY Appoints Michael Wyzga as CFO and adds Jean Franchi to its Board of Directors Read More
Sariette Witte 1/19/23 Sariette Witte 1/19/23 VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters Read More
